Elise Van Caelenberg

Dr. Elise Van Caelenberg

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RSReinhart Speeckaert
Reinhart Speeckaert
ECElise Van Caelenberg
Elise Van Caelenberg
ABArno Belpaire
Arno Belpaire
Marijn M. SpeeckaertMarijn M. Speeckaert
Marijn M. Speeckaert
NGNanja Van Geel
Nanja Van Geel
Recent advances in vitiligo have provided promising treatment options, particularly through understanding the immune-mediated mechanisms leading to depigmentation. The inflammatory components in both vitiligo (non-segmental) and segmental vitiligo have similarities. Both are believed to result from an immune-based destruction of melanocytes by anti-melanocyte-specific cytotoxic T cells. The JAK-STAT pathway is activated with IFN-γ as the crucial cytokine and Th1-associated chemokines such as CXCL9 and CXCL10 recruit immune cells towards vitiligo skin. Nonetheless, clear differences are also present, such as the localized nature of segmental vitiligo, likely due to somatic mosaicism and increased presence of poliosis. The differing prevalence of poliosis suggests that the follicular immune privilege, which is known to involve immune checkpoints, may be more important in vitiligo (non-segmental). Immunomodulatory therapies, especially those targeting the JAK-IFNγ pathway, are currently at the forefront, offering effective inhibition of melanocyte destruction by cytotoxic T cells. Although Janus Kinase (JAK) inhibitors demonstrate high repigmentation rates, optimal results can take several months to years. The influence of environmental UV exposure on repigmentation in patients receiving immunomodulating drugs remains largely underexplored. Nonetheless, the combined effect of phototherapy with JAK inhibitors is impressive and suggests a targeted immune-based treatment may still require additional stimulation of melanocytes for repigmentation. Identifying alternative melanocyte stimulants beyond UV light remains crucial for the future management of vitiligo.

3 September 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ECElise Van Caelenberg
Elise Van Caelenberg
ABArno Belpaire
Arno Belpaire
NGNanja van Geel
Nanja van Geel
RSReinhart Speeckaert
Reinhart Speeckaert
A deeper understanding of the immune-based pathogenesis of alopecia areata is essential for the development of novel targeted therapies. Compared to cytokines, chemokines exhibit substantially higher serum concentrations, offering a more robust approach for large-scale immune profiling. However, the complexity of chemokine interactions presents challenges in defining their precise roles in AA. To explore these dynamics, we conducted a scoping review and meta-analysis of 46 original research articles examining chemokine expression in skin and blood samples from AA patients; meta-analysis was performed when three or more studies assessed the same chemokine in comparable groups. Th1-associated chemokines—including CXCL9, CXCL10, CCL5, and CXCL11—were consistently elevated in AA, reflecting the known IFN-γ–driven response. A distinct Th2 chemokine signature was also observed, with increased levels of CCL13, CCL17, CCL22, and CX3CL1. Additionally, elevated levels of CCL2, CCL3, CCL4 (monocyte/dendritic cell recruitment), and CCL11, CCL24, and CCL26 (eosinophil recruitment) suggest the involvement of immune pathways beyond classical T helper subsets. Meta-analysis confirmed significantly elevated serum levels of CXCL9 (p = 0.003), CXCL10 (p = 0.004), CXCL8 (p < 0.001), and CCL17 (p < 0.001). These findings reveal a complex chemokine profile in AA, dominated by Th1 activity but also implicating Th2 and other immune pathways, highlighting the potential benefit of broader immunomodulatory strategies to address the multifaceted immune dysregulation underlying the disease.

7 March 2025 in Journal of Translational Autoimmunity
Verified
Journal Article
Open access
ABArno Belpaire
Arno Belpaire
ADAnnelies Demeyer
Annelies Demeyer
ECElise Van Caelenberg
Elise Van Caelenberg
NGNanja Van Geel
Nanja Van Geel
RSReinhart Speeckaert
Reinhart Speeckaert
Despite significant progress in the treatment of alopecia areata (AA), many aspects of its immune-based pathogenesis remain unexplored. IFN-γ, primarily produced by CD8+ T cells and NK cells, is considered central to AA pathogenesis. However, the complex immune signaling network contributes to therapeutic resistance and frequent disease flares after treatment discontinuation. The aryl hydrocarbon receptor (AhR) pathway, upregulated by IFN-γ, modulates Th17 responses, but its inhibitory effects on IFN-γ remain unclear. Although IL-17 levels are elevated in AA, clinical trials indicate that IL-17A inhibitors are ineffective. AhR expression is known to induce immune checkpoints (ICPs) such as PD-1, suggesting a potential role as a negative feedback mechanism. This study investigated AhR expression in lymphocytes from AA patients and its association with clinical and laboratory markers of disease activity. AhR expression was significantly reduced in CD4, CD8, Th1, and Th17 lymphocytes in AA patients compared to healthy controls (p < 0.005), and it correlated inversely with SALTII scores (p < 0.05). ROC analysis showed that AhR levels in CD8 cells could differentiate mild AA from healthy controls with a sensitivity of 82.35 % and specificity of 86.84 %, suggesting potential diagnostic utility. Lower AhR levels were associated with increased IFN-γ+ lymphocytes and decreased IL-17+ immune cells. Interestingly, immune profiles differed between atopic and non-atopic patients: in severe AA, higher AhR expression was linked to increased sPD-1 concentrations, whereas in limited AA, AhR failed to upregulate any investigated ICP. These findings highlight the significant downregulation of the AhR pathway in AA and suggest its potential as a therapeutic target. Future research should explore the development of AhR agonists or antagonists to modulate immune responses in AA.